Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 22, 2026, 6:56 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Intervention: ADM Clear all
Completed Phase 2 Interventional Results available

A Study to Assess the Efficacy and Safety of Farletuzumab (MORAb 003) in Combination With Carboplatin Plus Paclitaxel or Carboplatin Plus Pegylated Liposomal Doxorubicin (PLD) in Participants With Low CA125 Platinum-sensitive Ovarian Cancer

NCT02289950
View directory record Official record
Conditions
Platinum-Sensitive Ovarian Cancer in First Relapse
Interventions
Farletuzumab, Placebo
Drug
Lead sponsor
Eisai Inc.
Industry
Eligibility
18 Years and older · Female only
Enrollment
332 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2020
U.S. locations
35
States / cities
Phoenix, Arizona • Los Angeles, California • Orange, California + 32 more
Source: ClinicalTrials.gov public record
Updated Sep 1, 2021 · Synced Sep 22, 2026, 6:56 PM EDT
Recruiting No phase listed Observational

Impact of Highly Effective Modulator Therapy on the Cystic Fibrosis Microbiome

NCT05982795
View directory record Official record
Conditions
Cystic Fibrosis
Interventions
Nasal endoscopy with microbiome swab and mucus collection through filter paper and sponge, Olfactory Function Testing, Survey Completion
Other
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years to 99 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2023 – 2026
U.S. locations
1
States / cities
Lebanon, New Hampshire
Source: ClinicalTrials.gov public record
Updated Dec 15, 2025 · Synced Sep 22, 2026, 6:56 PM EDT
Active, not recruiting Phase 2 Interventional

UARK 2008-02 A Trial for High-risk Myeloma Evaluating Accelerating and Sustaining Complete Remission

NCT00869232
View directory record Official record
Conditions
Multiple Myeloma
Interventions
Velcade, Melphalan, Thalidomide, Dexamethasone, Cisplatin, Adriamycin, Cyclophosphamide, Etoposide
Drug
Lead sponsor
University of Arkansas
Other
Eligibility
18 Years to 75 Years
Enrollment
90 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2028
U.S. locations
1
States / cities
Little Rock, Arkansas
Source: ClinicalTrials.gov public record
Updated May 21, 2026 · Synced Sep 22, 2026, 6:56 PM EDT
Active, not recruiting Not applicable Interventional Accepts healthy volunteers

Using Structured Video Chat to Improve Relationships Between Young Children and Remote Grandparents

NCT06071832
View directory record Official record
Conditions
Child Development, Family Members, Grandparents
Interventions
Instructions for family Zoom session
Other
Lead sponsor
Lafayette College
Other
Eligibility
18 Months to 5 Years
Enrollment
540 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2025
U.S. locations
1
States / cities
Easton, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Mar 4, 2025 · Synced Sep 22, 2026, 6:56 PM EDT
Terminated No phase listed Observational

An Electronic Registry to Improve Adherence to Active Surveillance Monitoring at a Safety-net Hospital

NCT03553732
View directory record Official record
Conditions
Prostatic Neoplasms
Interventions
Registry
Other
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older · Male only
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
1
States / cities
San Francisco, California
Source: ClinicalTrials.gov public record
Updated Aug 3, 2022 · Synced Sep 22, 2026, 6:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers Results available

Active You: Walk, Dance, and Tone Your Abs to Reduce Your Risk of Diabetes

NCT06127251
View directory record Official record
Conditions
Obesity
Interventions
PATH Intervention, Control Group, Physical activity tracker, Dietary education
Behavioral · Device
Lead sponsor
Emory University
Other
Eligibility
18 Years and older
Enrollment
54 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2024 – 2025
U.S. locations
1
States / cities
Atlanta, Georgia
Source: ClinicalTrials.gov public record
Updated Jul 21, 2026 · Synced Sep 22, 2026, 6:56 PM EDT
Not listed Not applicable Interventional Accepts healthy volunteers

Chrononutrition and Adolescent Weight Control

NCT04256863
View directory record Official record
Conditions
Adolescent Obesity, Diet, Weight Loss, Sleep
Interventions
Breakfast / Lunch, Dinner (DIN)
Behavioral
Lead sponsor
The Miriam Hospital
Other
Eligibility
13 Years to 17 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2021
U.S. locations
1
States / cities
Providence, Rhode Island
Source: ClinicalTrials.gov public record
Updated Sep 1, 2020 · Synced Sep 22, 2026, 6:56 PM EDT
Completed Not applicable Interventional

Improving Well-Being for Breast Cancer Patients

NCT02707471
View directory record Official record
Conditions
Self-management Intervention (SM-AET), General Health Education
Interventions
SM-AET, general health education
Behavioral
Lead sponsor
Duke University
Other
Eligibility
21 Years and older · Female only
Enrollment
312 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2023
U.S. locations
1
States / cities
Durham, North Carolina
Source: ClinicalTrials.gov public record
Updated Nov 12, 2023 · Synced Sep 22, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Therapy for Children With Advanced Stage Neuroblastoma

NCT01857934
View directory record Official record
Conditions
Neuroblastoma
Interventions
cyclophosphamide, topotecan, hu14.18K322A, peripheral blood stem cell harvest, surgical resection, cisplatin, etoposide, doxorubicin, vincristine, busulfan, melphalan, peripheral blood stem cell transplantation, natural killer cell infusion, radiation therapy, GM-CSF, G-CSF, mesna, levetiracetam, interleukin-2, Isotretinoin, CliniMACS
Drug · Biological · Procedure + 2 more
Lead sponsor
St. Jude Children's Research Hospital
Other
Eligibility
Up to 18 Years
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Sep 21, 2026 · Synced Sep 22, 2026, 6:56 PM EDT
Completed Phase 3 Interventional Results available

Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma

NCT00346164
View directory record Official record
Conditions
Adult Alveolar Soft-part Sarcoma, Adult Angiosarcoma, Adult Epithelioid Sarcoma, Adult Extraskeletal Chondrosarcoma, Adult Extraskeletal Osteosarcoma, Adult Fibrosarcoma, Adult Leiomyosarcoma, Adult Liposarcoma, Adult Malignant Fibrous Histiocytoma, Adult Malignant Hemangiopericytoma, Adult Malignant Mesenchymoma, Adult Neurofibrosarcoma, Adult Synovial Sarcoma, Childhood Alveolar Soft-part Sarcoma, Childhood Angiosarcoma, Childhood Epithelioid Sarcoma, Childhood Fibrosarcoma, Childhood Leiomyosarcoma, Childhood Liposarcoma, Childhood Malignant Mesenchymoma, Childhood Neurofibrosarcoma, Childhood Synovial Sarcoma, Dermatofibrosarcoma Protuberans, Metastatic Childhood Soft Tissue Sarcoma, Nonmetastatic Childhood Soft Tissue Sarcoma, Stage I Adult Soft Tissue Sarcoma, Stage II Adult Soft Tissue Sarcoma, Stage III Adult Soft Tissue Sarcoma, Stage IV Adult Soft Tissue Sarcoma
Interventions
doxorubicin hydrochloride, clinical observation, therapeutic conventional surgery, 3-dimensional conformal radiation therapy, ifosfamide
Drug · Other · Procedure + 1 more
Lead sponsor
Children's Oncology Group
Network
Eligibility
Up to 29 Years
Enrollment
588 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2022
U.S. locations
165
States / cities
Birmingham, Alabama • Phoenix, Arizona • Tucson, Arizona + 133 more
Source: ClinicalTrials.gov public record
Updated Apr 27, 2022 · Synced Sep 22, 2026, 6:56 PM EDT
Completed Phase 4 Interventional

Motivation Project: Testing Intervention Components for the Smoker Who is Unwilling to Quit

NCT02354872
View directory record Official record
Conditions
Smoking, Motivation, Smoking Cessation
Interventions
Nicotine Mini-Lozenge, Behavioral Reduction Counseling, 5Rs Motivation Counseling, Behavioral Activation Counseling, No Treatment
Drug · Behavioral · Other
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
577 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2019
U.S. locations
1
States / cities
Madison, Wisconsin
Source: ClinicalTrials.gov public record
Updated Sep 21, 2020 · Synced Sep 22, 2026, 6:56 PM EDT
Terminated Phase 1Phase 2 Interventional Results available

Doxil® + Melphalan + Velcade (DMV) in Relapsed/Refractory Multiple Myeloma

NCT00985907
View directory record Official record
Conditions
Multiple Myeloma, Patient Participation
Interventions
Doxil, melphalan, bortezomib
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
18 Years and older
Enrollment
13 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2010
U.S. locations
2
States / cities
San Francisco, California • New York, New York
Source: ClinicalTrials.gov public record
Updated Jun 16, 2020 · Synced Sep 22, 2026, 6:56 PM EDT
Terminated Not applicable Interventional Accepts healthy volunteers

Study Using Dexmedetomidine to Decreases Emergence Delirium in Pediatric Patients

NCT00778063
View directory record Official record
Conditions
Otitis Media
Interventions
dexmedetomidine, saline
Drug
Lead sponsor
Ochsner Health System
Other
Eligibility
1 Year to 5 Years
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2008 – 2013
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Apr 12, 2023 · Synced Sep 22, 2026, 6:56 PM EDT
Completed No phase listed Observational Results available

Comparison Neuromuscular Blockade Monitors

NCT05006807
View directory record Official record
Conditions
Neuromuscular Blockade
Interventions
Mechanomyograph Twitch Monitor, Stimpod Twitch Monitor, TetraGraph Twitch Monitor, TwitchView Twitch Monitor, Nihon Kohden Twitch Monitor, Palpation of twitch count
Device · Other
Lead sponsor
University of Washington
Other
Eligibility
18 Years to 100 Years
Enrollment
51 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2024
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Jul 7, 2026 · Synced Sep 22, 2026, 6:56 PM EDT
Completed Phase 1 Interventional Results available

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

NCT03800836
View directory record Official record
Conditions
Breast Cancer
Interventions
Ipatasertib, Paclitaxel, Atezolizumab, Nab-Paclitaxel, AC
Drug
Lead sponsor
Hoffmann-La Roche
Industry
Eligibility
18 Years and older
Enrollment
139 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2022
U.S. locations
1
States / cities
Long Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 29, 2024 · Synced Sep 22, 2026, 6:56 PM EDT
Completed Phase 1Phase 2 Interventional Accepts healthy volunteers Results available

Project Impact 2: A Culturally Tailored Smoking Cessation Intervention for Latino Smokers

NCT02596711
View directory record Official record
Conditions
Tobacco Use Cessation, Cancer Prevention
Interventions
Nicotine Patch, Questionnaires, Carbon Monoxide (CO) Test, Health Education and Handouts, Culturally Tailored Reading Materials, Counseling Sessions
Drug · Behavioral · Other
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
26 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2015 – 2017
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Mar 9, 2020 · Synced Sep 22, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Study of Dose-dense Adriamycin Plus Cytoxan (AC) Followed by Either ABI-007 (Abraxane) or Taxol With Bevacizumab as Adjuvant Therapy for Patients With Breast Cancer

NCT00394251
View directory record Official record
Conditions
Breast Cancer
Interventions
Adriamycin and Cytoxan (AC), ABI-007, Taxol, Bevacizumab, pegfilgrastim
Drug
Lead sponsor
Celgene
Industry
Eligibility
18 Years to 70 Years · Female only
Enrollment
197 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2008
U.S. locations
27
States / cities
Birmingham, Alabama • Sedona, Arizona • Denver, Colorado + 23 more
Source: ClinicalTrials.gov public record
Updated Nov 24, 2019 · Synced Sep 22, 2026, 6:56 PM EDT
Active, not recruiting No phase listed Observational Accepts healthy volunteers

Prospective Validation of an EHR-based Pancreatic Cancer Risk Model

NCT05973331
View directory record Official record
Conditions
Pancreatic Adenocarcinoma, Predictive Cancer Model
Interventions
Pancreatic Cancer Risk Model (PRISM)
Other
Lead sponsor
Beth Israel Deaconess Medical Center
Other
Eligibility
40 Years to 100 Years
Enrollment
6,134,060 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 21, 2026 · Synced Sep 22, 2026, 6:56 PM EDT
Active, not recruiting Phase 2 Interventional

Brentuximab Vedotin and Nivolumab in Treating Patients With Early Stage Classic Hodgkin Lymphoma

NCT03712202
View directory record Official record
Conditions
Ann Arbor Stage I Hodgkin Lymphoma, Ann Arbor Stage I Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage I Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IA Hodgkin Lymphoma, Ann Arbor Stage IB Hodgkin Lymphoma, Ann Arbor Stage II Hodgkin Lymphoma, Ann Arbor Stage IIA Hodgkin Lymphoma, Ann Arbor Stage IIB Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma, Ann Arbor Stage I Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Lymphocyte-Depleted Classic HL, Ann Arbor Stage II Mixed Cellularity Classic HL, Ann Arbor Stage II Nodular Sclerosis Classic HL
Interventions
Bleomycin, Brentuximab Vedotin, Dacarbazine, Doxorubicin, Nivolumab, Quality-of-Life Assessment, Vinblastine
Drug · Biological · Other
Lead sponsor
City of Hope Medical Center
Other
Eligibility
16 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2024
U.S. locations
17
States / cities
Birmingham, Alabama • Duarte, California • San Diego, California + 12 more
Source: ClinicalTrials.gov public record
Updated Nov 5, 2024 · Synced Sep 22, 2026, 6:56 PM EDT
Completed Not applicable Interventional Accepts healthy volunteers

Resources to Enhance the Adjustment of Children (REACH)

NCT00820001
View directory record Official record
Conditions
Oppositional Defiant Disorder, Conduct Disorder, Attention Deficit Hyperactivity Disorder
Interventions
Booster Treatment, No-Booster, No intervention, Treatment As Usual
Behavioral · Other
Lead sponsor
University of Pittsburgh
Other
Eligibility
6 Years to 11 Years
Enrollment
254 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2003 – 2009
U.S. locations
2
States / cities
Cincinnati, Ohio • Pittsburgh, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Feb 17, 2013 · Synced Sep 22, 2026, 6:56 PM EDT
Completed Phase 2 Interventional Results available

Gemcitabine and Doxorubicin in Treating Patients With Recurrent or Progressive Head and Neck Cancer

NCT00509665
View directory record Official record
Conditions
Head and Neck Cancer
Interventions
doxorubicin hydrochloride, gemcitabine hydrochloride
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years to 120 Years
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2011
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jul 11, 2018 · Synced Sep 22, 2026, 6:56 PM EDT
Completed Phase 3 Interventional Results available

Evaluate the Use of Paravertebral Block in Reconstructive Breast Surgery

NCT00542542
View directory record Official record
Conditions
Breast Cancer
Interventions
Paravertebral Block, Propofol, Fentanyl, Ropivacaine, Midazolam
Procedure · Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
89 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2014
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 12, 2015 · Synced Sep 22, 2026, 6:56 PM EDT
Completed Not applicable Interventional Results available

ENGAGED 2 Study: Experiences With Mammography Screening and Breast Density 2

NCT03029286
View directory record Official record
Conditions
Breast Density, Breast Cancer Female
Interventions
Usual Care Arm, Personalized Web Intervention Arm
Behavioral
Lead sponsor
Georgetown University
Other
Eligibility
40 Years to 69 Years · Female only
Enrollment
995 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2019
U.S. locations
1
States / cities
Seattle, Washington
Source: ClinicalTrials.gov public record
Updated Apr 29, 2025 · Synced Sep 22, 2026, 6:56 PM EDT
Completed No phase listed Observational Accepts healthy volunteers

Use of a Functional Neuroimaging Battery for the Evaluation of a Meditation Retreat

NCT02443766
View directory record Official record
Conditions
Healthy
Interventions
Meditation Retreat
Other
Lead sponsor
Thomas Jefferson University
Other
Eligibility
18 Years and older
Enrollment
14 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2017
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 24, 2022 · Synced Sep 22, 2026, 6:56 PM EDT